Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,819
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Self-citationThe genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Self-citationLouis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4648 · Cited by 911
Self-citationGD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., et al. (2022) · Nature · doi:10.1038/s41586-022-04489-4 · Cited by 823
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Auslander, N., Zhang, G., Lee, J. S., Frederick, D. T., Miao, B., Moll, T., Tian, T., Wei, Z., Madan, S., Sullivan, R. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0157-9 · Cited by 738
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
“Patients in the immunotherapy treatment group had significantly improved event-free survival and overall survival as compared to the patients that received the standard of care alone (53).”
ResultGD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., Mastronuzzi, A., Cefalo, M. G., Pagliara, D., Amicucci, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2210859 · Cited by 561
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
Declining childhood and adolescent cancer mortality
Smith, M. A., Altekruse, S. F., Adamson, P. C., Reaman, G. H., & Seibel, N. L. (2014) · Cancer · doi:10.1002/cncr.28748 · Cited by 542
“approval, may provide a blueprint for how such agents can be developed.(21) In addition, recent legislative initiatives such as the Creating Hope Act may stimulate the de-”
BackgroundSelf-citationHeczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
Mount, C. W., Majzner, R. G., Sundaresh, S., Arnold, E. P., Kadapakkam, M., Haile, S., Labanieh, L., Hulleman, E., Woo, P. J., Rietberg, S. P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0006-x · Cited by 499
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00278 · Cited by 494
“Patients were designated as low-risk (LR),(24) intermediaterisk (IR),(22,25) or HR using the COG v1 classifier and treated accordingly.(10,13,26,27)”
BackgroundMethodSelf-citationThe clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Smith, B. A. H., & Bertozzi, C. R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00093-1 · Cited by 500
Engineering CAR-T cells: Design concepts
Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 485
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Advancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 407
Self-citationLadenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Brock, P., Michon, J. M., Owens, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30578-3 · Cited by 418
Gargett, T., & Brown, M. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00235 · Cited by 395
Sausen, M., Leary, R. J., Jones, S., Wu, J., Reynolds, C. P., Liu, X., Blackford, A., Parmigiani, G., Diaz, L. A., Papadopoulos, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2493 · Cited by 414
“We developed personalized rearrangement biomarkers to monitor circulating tumor DNA (ctDNA) in serial plasma samples from four additional cases of neuroblastoma obtained during a post-consolidation minimal residual disease (MRD) immunotherapy trial 39 (Supplementary Fig.”
Self-citationRetinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Overview and recent advances in the treatment of neuroblastoma
Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S., & Zage, P. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285230 · Cited by 394
“18 (dinutuximab) with cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) to standard isotretinoin maintenance therapy significantly improved shortterm survival in high-risk patients, with both higher EFS and OS rates compared to standard therapy after two years of follow-up [8…”
BackgroundIrwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388
“Current treatments rely on dose-intensive chemotherapy, radiation therapy, and immunotherapeutic targeting of the disialoganglioside GD2 (Maris, 2010; Yu et al., 2010).”
Self-citationMolecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 365
Neuroblastoma: Molecular Pathogenesis and Therapy
Louis, C. U., & Shohet, J. M. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-011514-023121 · Cited by 354
Park, J. R., Kreissman, S. G., London, W. B., Naranjo, A., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D., Shaw, P. J., Kraveka, J. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.11642 · Cited by 358
Self-citationLadenstein, R., Pötschger, U., Pearson, A. D. J., Brock, P., Luksch, R., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30070-0 · Cited by 350
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Nazha, B., Inal, C., & Owonikoko, T. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01000 · Cited by 324
“The randomized phase II ANBL1221 trial conducted by the COG compared the combination of irinotecan, temozolomide, and temsirolimumus with irinotecan, temozolomide, and dinutuximab plus GM-CSF in children with relapsed or refractory neuroblastoma (98).”
BackgroundInfluentialDavis, K. L., Fox, E., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30023-1 · Cited by 337
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Park, J. R., Bagatell, R., London, W. B., Maris, J. M., Cohn, S. L., Mattay, K. M., Hogarty, M., & on behalf of the COG Neuroblastoma Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24433 · Cited by 332
“High-risk therapy has evolved with incremental improvement in outcome, including the recent demonstration that GD2directed immunotherapy combined with cytokines significantly improves survival [17].”
BackgroundInfluentialSelf-citationPhase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0230 · Cited by 329
“In addition to the promising early clinical results seen with first-generation GD2-specific CAR T cells, clinical studies have also demonstrated improved survival in patients with high-risk neuroblastoma when mAbs to GD2 are administered in combination with standard therapy (21).”
Neuroblastoma: clinical and biological approach to risk stratification and treatment
Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304
Self-citationKreissman, S. G., Seeger, R. C., Matthay, K. K., London, W. B., Sposto, R., Grupp, S. A., Haas-Kogan, D. A., LaQuaglia, M. P., Yu, A. L., Diller, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70309-7 · Cited by 304
Self-citationMechanisms of neuroblastoma regression
Brodeur, G. M., & Bagatell, R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.168 · Cited by 284
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
“Anti-GD2 antibody has prolonged the survival of patients suffering from neuroblastoma.(121,122) The role of GD2 as a cancer target has been reviewed elsewhere.”
BackgroundAnti‐tumour strategies aiming to target tumour‐associated macrophages
Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H. (2013) · Immunology · doi:10.1111/imm.12023 · Cited by 278
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285
“Patients diagnosed with metastatic NBL-NA at age 18 months often have tumors with recurrent segmental genomic alterations and have high-risk disease with only 45% long-term disease-free survival.(10-16) In contrast, children diagnosed with metastatic NBL-NA at age 18 months of age frequently have tumors with whole chr…”
BackgroundMethodSelf-citationNeuroblastoma—A Neural Crest Derived Embryonal Malignancy
Johnsen, J. I., Dyberg, C., & Wickström, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00009 · Cited by 277
“Anti-GD2 antibodies have for the last 20 years been successfully applied as a treatment option for high-risk neuroblastoma and recent studies have shown further increased survival of patients with high-risk neuroblastoma treated with a combination of chimeric anti-GD2 antibodies, GM-CSF and IL-2 suggesting more system…”
BackgroundMethodMody, R., Naranjo, A., Van Ryn, C., Yu, A. L., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Sondel, P. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30355-8 · Cited by 277
Self-citationUpdates in Diagnosis, Management, and Treatment of Neuroblastoma
Swift, C. C., Eklund, M. J., Kraveka, J. M., & Alazraki, A. L. (2018) · RadioGraphics · doi:10.1148/rg.2018170132 · Cited by 279
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma
Diskin, S. J., Capasso, M., Schnepp, R. W., Cole, K. A., Attiyeh, E. F., Hou, C., Diamond, M., Carpenter, E. L., Winter, C., Lee, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2387 · Cited by 266
Self-citationCheung, N.-K. V., Cheung, I. Y., Kushner, B. H., Ostrovnaya, I., Chamberlain, E., Kramer, K., & Modak, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3807 · Cited by 263
Cancer mRNA vaccines: clinical advances and future opportunities
Sayour, E. J., Boczkowski, D., Mitchell, D. A., & Nair, S. K. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00902-1 · Cited by 234
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication
Theruvath, J., Menard, M., Smith, B. A. H., Linde, M. H., Coles, G. L., Dalton, G. N., Wu, W., Kiru, L., Delaidelli, A., Sotillo, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01625-x · Cited by 249
High-Risk Neuroblastoma Treatment Review
Smith, V., & Foster, J. (2018) · Children · doi:10.3390/children5090114 · Cited by 239
“In a randomized clinical trial, patients who received isotretinoin showed improvement in EFS, but not OS, over patients who did not [14,26].”
Spontaneous regression of neuroblastoma
Brodeur, G. M. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2761-2 · Cited by 235
“18) directed against the disialoganglioside GD2 has been incorporated into frontline treatment of patients with high-risk neuroblastoma (Yu et al. 2010) and preliminary studies have been carried out using adoptive immunotherapy in patients with recurrent/refractory disease (Louis et al. 2011).”
BackgroundIntravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Monje, M., Mahdi, J., Majzner, R., Yeom, K. W., Schultz, L. M., Richards, R. M., Barsan, V., Song, K.-W., Kamens, J., Baggott, C., et al. (2025) · Nature · doi:10.1038/s41586-024-08171-9 · Cited by 225
“Of note, we did not observe any cases of transient painful peripheral neuropathy commonly associated with anti-GD2 antibody therapy 29 .”
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 232
Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236
Novel Insights and Therapeutic Interventions for Pediatric Osteosarcoma
Kager, L., Tamamyan, G., & Bielack, S. (2017) · Future Oncology · doi:10.2217/fon-2016-0261 · Cited by 242
Tivnan, A., Orr, W. S., Gubala, V., Nooney, R., Williams, D. E., McDonagh, C., Prenter, S., Harvey, H., Domingo-Fernández, R., Bray, I. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038129 · Cited by 233
“7565%) at two years post-treatment [9], longer term survival rates have not yet been published.”
BackgroundInfluentialHirabayashi, K., Du, H., Xu, Y., Shou, P., Zhou, X., Fucá, G., Landoni, E., Sun, C., Chen, Y., Savoldo, B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00244-2 · Cited by 225
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Ochoa, M. C., Minute, L., Rodriguez, I., Garasa, S., Perez‐Ruiz, E., Inogés, S., Melero, I., & Berraondo, P. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2017.6 · Cited by 230
Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
Zhang, W., Xia, W., Lv, Z., Ni, C., Xin, Y., & Yang, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000458736 · Cited by 229
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Tarek, N., Le Luduec, J.-B., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N.-K. V., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62749 · Cited by 229
“Treatment of patients with high-risk NB with monoclonal antibodies (mAb) targeting the disialoganglioside surface antigen GD2 has resulted in lower recurrence rates and improved overall survival (OS) (3–5).”
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., Naranjo, A., Diccianni, M. B., Gan, J., Hank, J. A., Batova, A., London, W. B., Tenney, S. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3909 · Cited by 221
“The study met criteria for early stopping owing to efficacy, and randomization was halted (2).”
BackgroundMethodResultSelf-citationChildren's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
“In neuroblastoma anti-GD2 antibody significantly improves event free and overall survival [124].”
BackgroundBosse, K. R., Raman, P., Zhu, Z., Lane, M., Martinez, D., Heitzeneder, S., Rathi, K. S., Kendsersky, N. M., Randall, M., Donovan, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.003 · Cited by 215
“However, this therapy is quite toxic due to the presence of GD2 on nocireceptor-containing peripheral nerves, and relapses are common on or after therapy (Yu et al., 2010).”
BackgroundSelf-citationBosse, K. R., & Maris, J. M. (2016) · Cancer · doi:10.1002/cncr.29706 · Cited by 220
“Although it has been known for decades that retinoids can induce terminal differentiation of neuroblastoma cells in vitro, and the use of isotretinoin along with antiganglioside GD2-targeted immunotherapy has become the standard of neuroblastoma maintenance therapy, the response to retinoids is heterogeneous, and reti…”
BackgroundSelf-citationWienke, J., Dierselhuis, M. P., Tytgat, G. A. M., Künkele, A., Nierkens, S., & Molenaar, J. J. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.014 · Cited by 217
Challenging issues in pediatric oncology
Pui, C.-H., Gajjar, A. J., Kane, J. R., Qaddoumi, I. A., & Pappo, A. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.95 · Cited by 217
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
Mirzaei, H. R., Rodriguez, A., Shepphird, J., Brown, C. E., & Badie, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01850 · Cited by 217
“developed CAR T cells targeted to the validated tumor antigen GD2, for which the safety of monoclonal antibody therapy was previously demonstrated (49, 120).”
Cancer‐related circulating and tumor‐associated neutrophils – subtypes, sources and function
Shaul, M. E., & Fridlender, Z. G. (2018) · The FEBS Journal · doi:10.1111/febs.14524 · Cited by 216
Heczey, A., Xu, X., Courtney, A. N., Tian, G., Barragan, G. A., Guo, L., Amador, C. M., Ghatwai, N., Rathi, P., Wood, M. S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02363-y · Cited by 204
“Regarding other AEs, patients on our study and most other early-phase GD2-CAR-T cell studies did not experience neuropathic pain 11,13,14 , which commonly occurs with GD2-specific antibodies, including dinutuxi-mab, and can require intravenous opioid administration 32 .”
BackgroundAnti-GD2 immunotherapy for neuroblastoma
Sait, S., & Modak, S. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1364995 · Cited by 210
“31 induction chemotherapy.[3,4] Dinutuximab was the first immunotherapy to be FDA and EMA approved for children with any cancer.”
InfluentialChen, Y., Sun, C., Landoni, E., Metelitsa, L., Dotti, G., & Savoldo, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1811 · Cited by 204
“Because children with high-risk neuroblastoma continue to have poor outcome despite intensive chemotherapy regimens, new treatment strategies are required (2, 3).”
BackgroundMody, R., Yu, A. L., Naranjo, A., Zhang, F. F., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Hank, J. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00203 · Cited by 202
Self-citationYanik, G. A., Parisi, M. T., Shulkin, B. L., Naranjo, A., Kreissman, S. G., London, W. B., Villablanca, J. G., Maris, J. M., Park, J. R., Cohn, S. L., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112334 · Cited by 211
“In addition, 46 patients were enrolled onto COG ANBL0032 and treated with chimeric anti-GD2 antibody plus isotretinoin (4).”
BackgroundMethodSelf-citationNakagawara, A., Li, Y., Izumi, H., Muramori, K., Inada, H., & Nishi, M. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx176 · Cited by 197
“Immunotherapy using an anti-GD2 chimeric mAb is currently being evaluated as a treatment for MRD after high-dose chemotherapy in high-risk NB (2,310,314,348).”
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S., Wright, G., Thomas, S., Cheung, G. W.-K., Gileadi, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abd6169 · Cited by 202
Xu, X., Huang, W., Heczey, A., Liu, D., Guo, L., Wood, M., Jin, J., Courtney, A. N., Liu, B., Di Pierro, E. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0421 · Cited by 192
“Basedon results of a randomizedphase III clinical trial (39), the FDA approved anti-GD2 monoclonal antibody ch14.”
BackgroundPromising Therapeutic Targets in Neuroblastoma
Matthay, K. K., George, R. E., & Yu, A. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1939 · Cited by 187
Self-citationColon, N. C., & Chung, D. H. (2011) · Advances in Pediatrics · doi:10.1016/j.yapd.2011.03.011 · Cited by 180
Infarinato, N. R., Park, J. H., Krytska, K., Ryles, H. T., Sano, R., Szigety, K. M., Li, Y., Zou, H. Y., Lee, N. V., Smeal, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1056 · Cited by 183
Yu, J., Wu, X., Yan, J., Yu, H., Xu, L., Chi, Z., Sheng, X., Si, L., Cui, C., Dai, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0548-2 · Cited by 184
“Drug and Administration (FDA) for the treatment of neuroblastoma in March 2017 [15].”
BackgroundEsser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
“18-IL2 have been used in clinical trials for the treatment of NB to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2 tumour cells [18, 25, 26].”
InfluentialSelf-citationNeuroblastoma Origin and Therapeutic Targets for Immunotherapy
Kholodenko, I. V., Kalinovsky, D. V., Doronin, I. I., Deyev, S. M., & Kholodenko, R. V. (2018) · Journal of Immunology Research · doi:10.1155/2018/7394268 · Cited by 185
“The use of GD2-specific antibodies significantly increases the survival of patients [4] and is becoming the standard approach of therapy for this type of cancer [5].”
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 191
Pediatric cancer mortality and survival in the United States, 2001‐2016
Siegel, D. A., Richardson, L. C., Henley, S. J., Wilson, R. J., Dowling, N. F., Weir, H. K., Tai, E. W., & Buchanan Lunsford, N. (2020) · Cancer · doi:10.1002/cncr.33080 · Cited by 181
“Patients with neuroblastomas, who showed increased survival in this study over time, had improved outcomes in past studies in part because of advances in treatment such as the use of targeted antibody therapy.(5,47) The most common pediatric bone cancers (osteosarcomas and Ewing tumors) and soft-tissue sarcomas (rhabd…”
ResultNewman, E. A., Abdessalam, S., Aldrink, J. H., Austin, M., Heaton, T. E., Bruny, J., Ehrlich, P., Dasgupta, R., Baertschiger, R. M., Lautz, T. B., et al. (2019) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2018.09.004 · Cited by 178
Davidoff, A. M. (2012) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2011.10.009 · Cited by 178
Delgado, D. C., Hank, J. A., Kolesar, J., Lorentzen, D., Gan, J., Seo, S., Kim, K., Shusterman, S., Gillies, S. D., Reisfeld, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2211 · Cited by 179
Self-citationMajzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Self-citationZhu, E. F., Gai, S. A., Opel, C. F., Kwan, B. H., Surana, R., Mihm, M. C., Kauke, M. J., Moynihan, K. D., Angelini, A., Williams, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.004 · Cited by 177
Targeting ALK in neuroblastoma—preclinical and clinical advancements
Carpenter, E. L., & Mossé, Y. P. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.72 · Cited by 177
London, W. B., Bagatell, R., Weigel, B. J., Fox, E., Guo, D., Van Ryn, C., Naranjo, A., & Park, J. R. (2017) · Cancer · doi:10.1002/cncr.30934 · Cited by 175
Self-citationGanglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma
Roth, M., Linkowski, M., Tarim, J., Piperdi, S., Sowers, R., Geller, D., Gill, J., & Gorlick, R. (2014) · Cancer · doi:10.1002/cncr.28461 · Cited by 167
“Due to the relatively isolated expression of GD2 on malignant cells, it is an attractive target for antibody-mediated therapy and anti-GD2 antibodies have been shown to improve survival for patients with high-risk neuroblastoma.(5,13) To the best of our knowledge, the expression of GD2 on the cell surface of osteosarc…”
BackgroundResultZhang, B., Kracker, S., Yasuda, T., Casola, S., Vanneman, M., Hömig-Hölzel, C., Wang, Z., Derudder, E., Li, S., Chakraborty, T., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.031 · Cited by 172
Tumour-associated macrophages and cancer
Cook, J., & Hagemann, T. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.017 · Cited by 165
“Also, GM-CSF used in immunotherapy, has been implicated in ‘M1’ like polarisation, and has been investigated as the potential cause of increased macrophage infiltration and better outcome in neuroblastoma (NCT00026312) [70].”
BackgroundFederico, S. M., McCarville, M. B., Shulkin, B. L., Sondel, P. M., Hank, J. A., Hutson, P., Meagher, M., Shafer, A., Ng, C. Y., Leung, W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0379 · Cited by 162
“Toxicities including pain, hypotension, capillary leak, and hypersensitivity related to murine and chimeric anti-GD2 mAbs have limited their clinical use in a subset of patients (2, 12, 13).”
BackgroundSelf-citationvon Allmen, D., Davidoff, A. M., London, W. B., Van Ryn, C., Haas-Kogan, D. A., Kreissman, S. G., Khanna, G., Rosen, N., Park, J. R., & La Quaglia, M. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2642 · Cited by 167
Self-citation
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.